Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Burrows JN"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 21
Tytuł:
In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models
Autorzy:
Schleiferböck S
Scheurer C
Ihara M
Itoh I
Bathurst I
Burrows JN
Fantauzzi P
Lotharius J
Charman SA
Morizzi J
Shackleford DM
White KL
Brun R
Wittlin S
Pokaż więcej
Temat:
Therapeutics. Pharmacology
RM1-950
Źródło:
Drug Design, Development and Therapy, Vol 2013, Iss default, Pp 1377-1384 (2013)
Opis pliku:
electronic resource
Relacje:
http://www.dovepress.com/in-vitro-and-in-vivo-characterization-of-the-antimalarial-lead-compoun-peer-reviewed-article-DDDT; https://doaj.org/toc/1177-8881
Dostęp URL:
https://doaj.org/article/6773d4e37552455dbfc42e04686fdcb5  Link otwiera się w nowym oknie
Czasopismo naukowe
Szczegóły
Tytuł:
Development and application of a PBPK modeling strategy to support antimalarial drug development.
Autorzy:
Abla N; Medicines for Malaria Venture, Geneva, Switzerland.
Howgate E; Certara UK Ltd, Simcyp Division, Sheffield, UK.
Rowland-Yeo K; Certara UK Ltd, Simcyp Division, Sheffield, UK.
Dickins M; Certara UK Ltd, Simcyp Division, Sheffield, UK.
Bergagnini-Kolev MC; Certara UK Ltd, Simcyp Division, Sheffield, UK.
Chen KF; Certara UK Ltd, Simcyp Division, Sheffield, UK.
McFeely S; Certara UK Ltd, Simcyp Division, Sheffield, UK.
Bonner JJ; Certara UK Ltd, Simcyp Division, Sheffield, UK.
Santos LGA; Certara UK Ltd, Simcyp Division, Sheffield, UK.
Gobeau N; Medicines for Malaria Venture, Geneva, Switzerland.
Burt H; Certara UK Ltd, Simcyp Division, Sheffield, UK.
Barter Z; Certara UK Ltd, Simcyp Division, Sheffield, UK.
Jones HM; Certara UK Ltd, Simcyp Division, Sheffield, UK.
Wesche D; Certara USA, Integrated Drug Development, Grand Rapids, Michigan, USA.
Charman SA; Monash University, Melbourne, Victoria, Australia.
Möhrle JJ; Medicines for Malaria Venture, Geneva, Switzerland.
Burrows JN; Medicines for Malaria Venture, Geneva, Switzerland.
Almond LM; Certara UK Ltd, Simcyp Division, Sheffield, UK.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Sep; Vol. 12 (9), pp. 1335-1346. Date of Electronic Publication: 2023 Aug 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antimalarials*
Humans ; Drug Development ; Research Design ; Universities
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Plasmodium falciparum Viability after Antimalarial Treatment In Vitro.
Autorzy:
Walz A; Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.; University of Basel, 4001 Basel, Switzerland.
Duffey M; Medicines for Malaria Venture, 1215 Geneva, Switzerland.
Aljayyoussi G; Medicines for Malaria Venture, 1215 Geneva, Switzerland.; Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool L3 5QA, UK.
Sax S; Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.; University of Basel, 4001 Basel, Switzerland.
Leroy D; Medicines for Malaria Venture, 1215 Geneva, Switzerland.
Besson D; Medicines for Malaria Venture, 1215 Geneva, Switzerland.
Burrows JN; Medicines for Malaria Venture, 1215 Geneva, Switzerland.
Cherkaoui-Rbati MH; Medicines for Malaria Venture, 1215 Geneva, Switzerland.
Gobeau N; Medicines for Malaria Venture, 1215 Geneva, Switzerland.
Westwood MA; Swiss BioQuant, 4153 Reinach, Switzerland.
Siethoff C; Swiss BioQuant, 4153 Reinach, Switzerland.
Gamo FJ; Global Health Medicines, GlaxoSmithKline I+D, 28760 Madrid, Spain.
Mäser P; Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.; University of Basel, 4001 Basel, Switzerland.
Wittlin S; Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.; University of Basel, 4001 Basel, Switzerland.
Pokaż więcej
Źródło:
Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2023 Jan 23; Vol. 16 (2). Date of Electronic Publication: 2023 Jan 23.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Antifungal Itraconazole Is a Potent Inhibitor of Chikungunya Virus Replication.
Autorzy:
Policastro LR; São Carlos Institute of Physics, University of São Paulo, São Carlos 13563-120, Brazil.
Dolci I; São Carlos Institute of Physics, University of São Paulo, São Carlos 13563-120, Brazil.
Godoy AS; São Carlos Institute of Physics, University of São Paulo, São Carlos 13563-120, Brazil.
Silva Júnior JVJ; Virology Sector, Department of Preventive Veterinary Medicine, Federal University of Santa Maria, Santa Maria 97105-900, Brazil.; Virology Sector, Laboratory of Immunopathology Keizo Asami, Federal University of Pernambuco, Recife 50670-901, Brazil.
Ruiz UEA; Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia 38405-302, Brazil.
Santos IA; Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia 38405-302, Brazil.
Jardim ACG; Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia 38405-302, Brazil.; Institute of Biosciences, Humanities and Exact Sciences (Ibilce), São Paulo State University (UNESP), Campus São José do Rio Preto, São Josédo Rio Preto 15054-000, Brazil.
Samby K; Medicines for Malaria Venture, P.O. Box 1826, 1215 Geneva, Switzerland.
Burrows JN; Medicines for Malaria Venture, P.O. Box 1826, 1215 Geneva, Switzerland.
Wells TNC; Medicines for Malaria Venture, P.O. Box 1826, 1215 Geneva, Switzerland.
Gil LHVG; Aggeu Magalhães Institute, IAM-FIOCRUZ, Recife 50670-420, Brazil.
Oliva G; São Carlos Institute of Physics, University of São Paulo, São Carlos 13563-120, Brazil.
Fernandes RS; São Carlos Institute of Physics, University of São Paulo, São Carlos 13563-120, Brazil.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Jun 21; Vol. 14 (7). Date of Electronic Publication: 2022 Jun 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Chikungunya Fever*/drug therapy
Chikungunya virus*/genetics
Viruses*/genetics
Antifungal Agents/metabolism ; Antifungal Agents/pharmacology ; Antifungal Agents/therapeutic use ; Antiviral Agents/therapeutic use ; Humans ; Itraconazole/pharmacology ; Luciferases ; RNA, Viral/genetics ; Virus Replication
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Actives from MMV Open Access Boxes? A suggested way forward.
Autorzy:
Samby K; Medicines for Malaria Venture, Geneva, Switzerland.
Willis PA; Medicines for Malaria Venture, Geneva, Switzerland.
Burrows JN; Medicines for Malaria Venture, Geneva, Switzerland.
Laleu B; Medicines for Malaria Venture, Geneva, Switzerland.
Webborn PJH; PJHW Consultancy Ltd, Marton, United Kingdom.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2021 Apr 22; Vol. 17 (4), pp. e1009384. Date of Electronic Publication: 2021 Apr 22 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Drug Discovery*
Validation Studies as Topic*
Malaria/*drug therapy
Neglected Diseases/*drug therapy
Access to Information ; Humans ; Tropical Medicine/methods
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
An in vitro toolbox to accelerate anti-malarial drug discovery and development.
Autorzy:
Charman SA; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia. .
Andreu A; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Barker H; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Blundell S; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Campbell A; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Campbell M; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Chen G; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Chiu FCK; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Crighton E; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Katneni K; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Morizzi J; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Patil R; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Pham T; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Ryan E; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Saunders J; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Shackleford DM; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
White KL; Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Almond L; Certara UK Limited, Simcyp Division, Level 2-Acero, 1 Concourse Way, Sheffield, S1 2BJ, UK.
Dickins M; Certara UK Limited, Simcyp Division, Level 2-Acero, 1 Concourse Way, Sheffield, S1 2BJ, UK.
Smith DA; 4 The Maltings, Walmer, Kent, CT14 7AR, UK.
Moehrle JJ; Medicines for Malaria Venture, PO Box 1826, 20 Route de Pré-Bois, CH-1215, Geneva 15, Switzerland.
Burrows JN; Medicines for Malaria Venture, PO Box 1826, 20 Route de Pré-Bois, CH-1215, Geneva 15, Switzerland.
Abla N; Medicines for Malaria Venture, PO Box 1826, 20 Route de Pré-Bois, CH-1215, Geneva 15, Switzerland.
Pokaż więcej
Źródło:
Malaria journal [Malar J] 2020 Jan 02; Vol. 19 (1), pp. 1. Date of Electronic Publication: 2020 Jan 02.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Development*
Drug Discovery*
Antimalarials/*metabolism
Antimalarials/*pharmacology
Antimalarials/blood ; Antimalarials/standards ; Caco-2 Cells ; Chromatography, Liquid ; Cytochrome P-450 Enzyme System/metabolism ; Drug Interactions ; Humans ; Kinetics ; Microsomes, Liver ; Permeability ; Protein Binding ; Solubility ; Tandem Mass Spectrometry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone.
Autorzy:
Skinner-Adams TS; 1Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD 4111 Australia.
Fisher GM; 1Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD 4111 Australia.
Riches AG; 2Commonwealth Scientific and Industrial Research Organization, Biomedical Manufacturing, Clayton, VIC 3168 Australia.
Hutt OE; 2Commonwealth Scientific and Industrial Research Organization, Biomedical Manufacturing, Clayton, VIC 3168 Australia.
Jarvis KE; 2Commonwealth Scientific and Industrial Research Organization, Biomedical Manufacturing, Clayton, VIC 3168 Australia.
Wilson T; 2Commonwealth Scientific and Industrial Research Organization, Biomedical Manufacturing, Clayton, VIC 3168 Australia.
von Itzstein M; 3Institute for Glycomics, Griffith University Gold Coast Campus, Gold Coast, QLD 4222 Australia.
Chopra P; 3Institute for Glycomics, Griffith University Gold Coast Campus, Gold Coast, QLD 4222 Australia.
Antonova-Koch Y; School of Medicine, University of California, San Diego, La Jolla, CA 92093 USA.; 7Present Address: California Institute for Biomedical Research (Calibr), La Jolla, CA 92037 USA.
Meister S; School of Medicine, University of California, San Diego, La Jolla, CA 92093 USA.; Present Address: Beckman Coulter Life Sciences in Indianapolis, Indianapolis, IN 46268 USA.
Winzeler EA; School of Medicine, University of California, San Diego, La Jolla, CA 92093 USA.
Clarke M; 1Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD 4111 Australia.
Fidock DA; 5Department of Microbiology and Immunology, and Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, NY 10032 USA.
Burrows JN; 6Medicines for Malaria Venture (MMV), Route de Pré Bois 20, Geneva, 1215 Switzerland.
Ryan JH; 2Commonwealth Scientific and Industrial Research Organization, Biomedical Manufacturing, Clayton, VIC 3168 Australia.
Andrews KT; 1Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD 4111 Australia.
Pokaż więcej
Źródło:
Communications biology [Commun Biol] 2019 May 03; Vol. 2, pp. 166. Date of Electronic Publication: 2019 May 03 (Print Publication: 2019).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antimalarials/*pharmacology
Atovaquone/*pharmacology
Enzyme Inhibitors/*pharmacology
Plasmodium berghei/*drug effects
Plasmodium falciparum/*drug effects
Proguanil/*analogs & derivatives
Animals ; Anopheles ; Antimalarials/chemistry ; Atovaquone/chemistry ; Cyclization/drug effects ; Dihydroorotate Dehydrogenase ; Dose-Response Relationship, Drug ; Drug Combinations ; Electron Transport Complex III/antagonists & inhibitors ; Electron Transport Complex III/metabolism ; Enzyme Inhibitors/chemistry ; Erythrocytes/drug effects ; Erythrocytes/parasitology ; Folic Acid/metabolism ; Hep G2 Cells ; Humans ; Inhibitory Concentration 50 ; Liver/drug effects ; Liver/parasitology ; Oxidoreductases Acting on CH-CH Group Donors/metabolism ; Plasmodium berghei/growth & development ; Plasmodium berghei/metabolism ; Plasmodium falciparum/growth & development ; Plasmodium falciparum/metabolism ; Proguanil/chemistry ; Proguanil/pharmacology ; Sporozoites/drug effects ; Sporozoites/growth & development ; Sporozoites/metabolism ; Terpenes/metabolism ; Triazines/chemistry ; Triazines/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria.
Autorzy:
Macintyre F; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva, Switzerland.
Ramachandruni H; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva, Switzerland.
Burrows JN; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva, Switzerland.
Holm R; Drug Product Development, Janssen R&D, Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.; Department of Science and Environment, Roskilde University, 4000, Roskilde, Denmark.
Thomas A; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva, Switzerland.
Möhrle JJ; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva, Switzerland.
Duparc S; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva, Switzerland.
Hooft van Huijsduijnen R; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva, Switzerland.
Greenwood B; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Gutteridge WE; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva, Switzerland.
Wells TNC; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva, Switzerland. .
Kaszubska W; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva, Switzerland.
Pokaż więcej
Źródło:
Malaria journal [Malar J] 2018 Nov 01; Vol. 17 (1), pp. 402. Date of Electronic Publication: 2018 Nov 01.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antimalarials*
Drug Development*
Drug Discovery*
Injections, Intravenous*
Malaria/*prevention & control
Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Assessing the anthelmintic activity of pyrazole-5-carboxamide derivatives against Haemonchus contortus.
Autorzy:
Jiao Y; Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, VIC, 3010, Australia.
Preston S; Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, VIC, 3010, Australia.; Faculty of Science and Technology, Federation University, Ballarat, VIC, 3350, Australia.
Song H; State Key Laboratory of Elemento-Organic Chemistry, Research Institute of Elemento-Organic Chemistry, Nankai University, Tianjin, 300071, China.
Jabbar A; Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, VIC, 3010, Australia.
Liu Y; State Key Laboratory of Elemento-Organic Chemistry, Research Institute of Elemento-Organic Chemistry, Nankai University, Tianjin, 300071, China.
Baell J; Medicinal Chemistry, Monash University Institute of Pharmaceutical Sciences (MIPS), Monash University, Parkville, VIC, 3052, Australia.
Hofmann A; Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, QLD, 4111, Australia.
Hutchinson D; Drug Discovery Biology, Monash University Institute of Pharmaceutical Sciences (MIPS), Monash University, Parkville, VIC, 3052, Australia.
Wang T; Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, VIC, 3010, Australia.
Koehler AV; Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, VIC, 3010, Australia.
Fisher GM; Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, QLD, 4111, Australia.
Andrews KT; Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, QLD, 4111, Australia.
Laleu B; Medicines for Malaria Venture (MMV), Route de Pré-Bois 20, CH-1215, Geneva, Switzerland.
Palmer MJ; Medicines for Malaria Venture (MMV), Route de Pré-Bois 20, CH-1215, Geneva, Switzerland.
Burrows JN; Medicines for Malaria Venture (MMV), Route de Pré-Bois 20, CH-1215, Geneva, Switzerland.
Wells TNC; Medicines for Malaria Venture (MMV), Route de Pré-Bois 20, CH-1215, Geneva, Switzerland.
Wang Q; State Key Laboratory of Elemento-Organic Chemistry, Research Institute of Elemento-Organic Chemistry, Nankai University, Tianjin, 300071, China. .
Gasser RB; Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, VIC, 3010, Australia. .; State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, 430070, China. .
Pokaż więcej
Źródło:
Parasites & vectors [Parasit Vectors] 2017 May 31; Vol. 10 (1), pp. 272. Date of Electronic Publication: 2017 May 31.
Typ publikacji:
Journal Article
MeSH Terms:
Anthelmintics/*pharmacology
Haemonchus/*drug effects
Pyrazoles/*chemistry
Pyrazoles/*pharmacology
Animals ; Biological Assay ; Drug Evaluation, Preclinical ; Haemonchiasis/drug therapy ; Haemonchiasis/mortality ; Haemonchiasis/veterinary ; Haemonchus/pathogenicity ; Larva/drug effects ; Mitochondria/drug effects ; Mitochondria/metabolism ; Mitochondrial Diseases ; Oxygen Consumption/drug effects ; Parasitic Sensitivity Tests ; Quaternary Ammonium Compounds/pharmacology ; Reproducibility of Results ; Ruminants/parasitology ; Toxicity Tests
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Erratum to: New developments in anti-malarial target candidate and product profiles.
Autorzy:
Burrows JN; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland.
Duparc S; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland.
Gutteridge WE; Neglected Infectious Diseases Consulting, Sevenoaks, Kent, UK.
van Huijsduijnen RH; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland.
Kaszubska W; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland.
Macintyre F; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland.
Mazzuri S; FSG, Rue de Chantepoulet 25, 1201, Geneva, Switzerland.
Möhrle JJ; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland.
Wells TNC; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland. .
Pokaż więcej
Źródło:
Malaria journal [Malar J] 2017 Apr 18; Vol. 16 (1), pp. 151. Date of Electronic Publication: 2017 Apr 18.
Typ publikacji:
Journal Article; Published Erratum
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
New developments in anti-malarial target candidate and product profiles.
Autorzy:
Burrows JN; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland.
Duparc S; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland.
Gutteridge WE; Neglected Infectious Diseases Consulting, Sevenoaks, Kent, UK.
Hooft van Huijsduijnen R; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland.
Kaszubska W; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland.
Macintyre F; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland.
Mazzuri S; FSG, Rue de Chantepoulet 25, 1201, Geneva, Switzerland.
Möhrle JJ; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland.
Wells TNC; Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland. .
Pokaż więcej
Źródło:
Malaria journal [Malar J] 2017 Jan 13; Vol. 16 (1), pp. 26. Date of Electronic Publication: 2017 Jan 13.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Antimalarials/*isolation & purification
Antimalarials/*pharmacology
Drug Discovery/*trends
Malaria/*drug therapy
Malaria/*prevention & control
Clinical Trials as Topic ; Drug Evaluation, Preclinical/trends ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Hit and lead criteria in drug discovery for infectious diseases of the developing world.
Autorzy:
Katsuno K; Global Health Innovative Technology (GHIT) Fund, Ark Hills, Sengokuyama Mori Tower (25F), 1-9-10 Roppongi, Minato-ku, Tokyo 106-0032, Japan.
Burrows JN; Medicines for Malaria Venture (MMV), 20, Route de Pré-Bois, 1215 Geneva 15, Switzerland.
Duncan K; Bill &Melinda Gates Foundation, PO Box 23350, Seattle, Washington 98102, USA.
Hooft van Huijsduijnen R; Medicines for Malaria Venture (MMV), 20, Route de Pré-Bois, 1215 Geneva 15, Switzerland.
Kaneko T; Global Alliance for TB Drug Development (TB Alliance), 40 Wall Street, 24th Floor, New York, New York 10005, USA.
Kita K; University of Tokyo, 7-3-1, Hongo, Bunkyo, Tokyo 113-0033, Japan.
Mowbray CE; Drugs for Neglected Diseases initiative (DNDi), 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland.
Schmatz D; Medicines for Malaria Venture (MMV), 20, Route de Pré-Bois, 1215 Geneva 15, Switzerland.
Warner P; Bill &Melinda Gates Foundation, PO Box 23350, Seattle, Washington 98102, USA.
Slingsby BT; Global Health Innovative Technology (GHIT) Fund, Ark Hills, Sengokuyama Mori Tower (25F), 1-9-10 Roppongi, Minato-ku, Tokyo 106-0032, Japan.
Pokaż więcej
Źródło:
Nature reviews. Drug discovery [Nat Rev Drug Discov] 2015 Nov; Vol. 14 (11), pp. 751-8. Date of Electronic Publication: 2015 Oct 05.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Developing Countries*/economics
Drug Discovery/*trends
Foundations/*trends
Malaria/*drug therapy
Neglected Diseases/*drug therapy
Tuberculosis/*drug therapy
Animals ; Communicable Diseases/drug therapy ; Communicable Diseases/economics ; Communicable Diseases/epidemiology ; Drug Discovery/economics ; Drugs, Generic/economics ; Drugs, Generic/therapeutic use ; Foundations/economics ; Humans ; Malaria/economics ; Malaria/epidemiology ; Neglected Diseases/economics ; Neglected Diseases/epidemiology ; Tuberculosis/economics ; Tuberculosis/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum.
Autorzy:
Avery VM
Bashyam S
Burrows JN
Duffy S
Papadatos G
Puthukkuti S
Sambandan Y
Singh S
Spangenberg T; Medicines for Malaria Venture MMV, ICC - Block G, 3rd Floor, route de Pré-Bois 20, PO Box 1826, 1215 Geneva 15, Switzerland. .
Waterson D
Willis P
Pokaż więcej
Źródło:
Malaria journal [Malar J] 2014 May 27; Vol. 13, pp. 190. Date of Electronic Publication: 2014 May 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Evaluation, Preclinical*
Small Molecule Libraries*
Antimalarials/*isolation & purification
Plasmodium falciparum/*drug effects
Algorithms ; Antimalarials/chemistry ; Antimalarials/pharmacology ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The open access malaria box: a drug discovery catalyst for neglected diseases.
Autorzy:
Spangenberg T; Medicines for Malaria Venture (MMV), Geneva, Switzerland. />Burrows JN
Kowalczyk P
McDonald S
Wells TN
Willis P
Pokaż więcej
Źródło:
PloS one [PLoS One] 2013 Jun 17; Vol. 8 (6), pp. e62906. Date of Electronic Publication: 2013 Jun 17 (Print Publication: 2013).
Typ publikacji:
Journal Article
MeSH Terms:
Drug Discovery*
Antimalarials/*pharmacology
Malaria, Falciparum/*drug therapy
Antimalarials/therapeutic use ; Drug Evaluation, Preclinical ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Designing the next generation of medicines for malaria control and eradication.
Autorzy:
Burrows JN; Medicines for Malaria Venture-MMV, PO Box 1826, Route de Pré-Bois 20, Geneva 151215, Switzerland.
van Huijsduijnen RH
Möhrle JJ
Oeuvray C
Wells TN
Pokaż więcej
Źródło:
Malaria journal [Malar J] 2013 Jun 06; Vol. 12, pp. 187. Date of Electronic Publication: 2013 Jun 06.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antimalarials/*isolation & purification
Drug Discovery/*methods
Malaria/*drug therapy
Malaria/*prevention & control
Antimalarials/pharmacokinetics ; Antimalarials/pharmacology ; Antimalarials/therapeutic use ; Drug Discovery/trends ; Drug Resistance ; Drug Stability ; Drug Therapy, Combination/methods ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The global pipeline of new medicines for the control and elimination of malaria.
Autorzy:
Anthony MP; Medicines for Malaria Venture (MMV), 20 rte de Pré-Bois 1215, Geneva, Switzerland.
Burrows JN
Duparc S
Moehrle JJ
Wells TN
Pokaż więcej
Źródło:
Malaria journal [Malar J] 2012 Sep 07; Vol. 11, pp. 316. Date of Electronic Publication: 2012 Sep 07.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antimalarials/*isolation & purification
Drug Discovery/*trends
Malaria/*drug therapy
Malaria/*prevention & control
Antimalarials/pharmacology ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 21

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies